MX2007002382A - Producci??n de anticuerpos anti-amiloides beta. - Google Patents

Producci??n de anticuerpos anti-amiloides beta.

Info

Publication number
MX2007002382A
MX2007002382A MX2007002382A MX2007002382A MX2007002382A MX 2007002382 A MX2007002382 A MX 2007002382A MX 2007002382 A MX2007002382 A MX 2007002382A MX 2007002382 A MX2007002382 A MX 2007002382A MX 2007002382 A MX2007002382 A MX 2007002382A
Authority
MX
Mexico
Prior art keywords
cumulative
culture
amino acid
glutamine
molar
Prior art date
Application number
MX2007002382A
Other languages
English (en)
Spanish (es)
Inventor
Denis Drapeau
Yen-Tuang Luan
James R Mercer
Wenge Wang
Daniel Lasko
Original Assignee
Wyeth Res Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Res Ireland Ltd filed Critical Wyeth Res Ireland Ltd
Publication of MX2007002382A publication Critical patent/MX2007002382A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/04—Plant cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2007002382A 2004-08-27 2005-08-26 Producci??n de anticuerpos anti-amiloides beta. MX2007002382A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60493604P 2004-08-27 2004-08-27
PCT/US2005/030364 WO2006026408A2 (en) 2004-08-27 2005-08-26 Production of anti-amyloid beta antibodies

Publications (1)

Publication Number Publication Date
MX2007002382A true MX2007002382A (es) 2007-06-15

Family

ID=35500647

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002382A MX2007002382A (es) 2004-08-27 2005-08-26 Producci??n de anticuerpos anti-amiloides beta.

Country Status (27)

Country Link
US (1) US7335491B2 (enExample)
EP (2) EP1781803B1 (enExample)
JP (3) JP2008511328A (enExample)
KR (1) KR100998857B1 (enExample)
CN (1) CN101048512B (enExample)
AR (1) AR050471A1 (enExample)
AU (1) AU2005280090A1 (enExample)
BR (1) BRPI0514680A (enExample)
CA (1) CA2578137C (enExample)
CR (1) CR8996A (enExample)
EC (1) ECSP077351A (enExample)
EG (1) EG25848A (enExample)
ES (1) ES2599103T3 (enExample)
HN (1) HN2005000486A (enExample)
IL (1) IL181587A (enExample)
MX (1) MX2007002382A (enExample)
MY (1) MY146097A (enExample)
NO (1) NO20071571L (enExample)
NZ (1) NZ591233A (enExample)
PE (2) PE20060715A1 (enExample)
RU (1) RU2418858C2 (enExample)
SG (1) SG155250A1 (enExample)
SV (1) SV2006002212A (enExample)
TW (1) TWI374935B (enExample)
UA (1) UA89644C2 (enExample)
WO (1) WO2006026408A2 (enExample)
ZA (1) ZA200702487B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
AU2006326284B2 (en) * 2005-12-12 2013-06-06 Ac Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
ES2668212T3 (es) 2006-07-13 2018-05-17 Wyeth Llc Producción de factor de coagulación IX con patrón de glucosilación mejorado
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
JP5401319B2 (ja) * 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
ES2538986T3 (es) * 2006-11-08 2015-06-25 Wyeth Llc Medios diseñados racionalmente para un cultivo celular
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
PL2115126T3 (pl) * 2007-03-02 2015-08-31 Wyeth Llc Zastosowanie miedzi i glutaminianu w hodowli komórkowej do wytwarzania polipeptydów
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CN105567627B (zh) 2007-04-26 2020-09-29 中外制药株式会社 使用含高浓度氨基酸的培养基的细胞培养方法
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2170389B1 (en) * 2007-06-12 2014-10-29 AC Immune S.A. Humanized antibodies to amyloid beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
SG10201505369QA (en) * 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
HUE027035T2 (hu) * 2008-04-17 2016-08-29 Wyeth Llc Eljárások csont morfogenetikus fehérjék termelésének fokozására
SI2326720T1 (en) 2008-09-15 2018-06-29 F. Hoffmann-La Roche Ag Substances and procedures for regulating cellular osmolality
FI2464725T4 (fi) 2009-08-11 2025-03-21 Hoffmann La Roche Proteiinien tuotanto glutamiinittomassa soluviljelyn elatusaineessa
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
PT2563904E (pt) 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
LT3330370T (lt) 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
RU2563353C2 (ru) 2010-04-26 2015-09-20 Новартис Аг Улучшенная среда для культивирования клеток
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
KR102358951B1 (ko) * 2011-07-01 2022-02-08 암젠 인크 포유동물 세포 배양
FI20115704L (fi) 2011-07-01 2013-01-02 Teknologian Tutkimuskeskus Vtt Oy Vierasproteiinien tuoton parantaminen
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
ES2678945T3 (es) 2013-10-11 2018-08-21 Regeneron Pharmaceuticals, Inc. Cultivos celulares optimizados metabólicamente
DE102017203908B3 (de) * 2017-03-09 2018-05-30 Evonik Technochemie Gmbh Kulturmedium, umfassend Oligopeptide
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
WO2018229274A1 (en) * 2017-06-16 2018-12-20 Katholieke Universiteit Leuven Cell culture media for differentiation of stem cells into hepatocytes
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
FI3818078T3 (fi) * 2018-07-03 2024-05-14 Bristol Myers Squibb Co Menetelmiä rekombinanttiproteiinien tuottamiseksi
AU2020398125C1 (en) 2019-12-06 2023-05-11 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021165302A1 (en) 2020-02-18 2021-08-26 Boehringer Ingelheim International Gmbh Mammalian cell culture processes
US12435129B2 (en) 2020-07-23 2025-10-07 Othair Prothena Limited Anti-Aβ antibodies

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8516415D0 (en) * 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1990003430A1 (en) * 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
WO1991005058A1 (en) 1989-10-05 1991-04-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
JPH059735A (ja) * 1991-07-09 1993-01-19 Kobe Steel Ltd ダイヤモンドの気相合成方法
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
CN1233189A (zh) * 1996-05-08 1999-10-27 弗·哈夫曼-拉罗切有限公司 用TNFR-Ig治疗哮喘
US6156570A (en) * 1997-03-20 2000-12-05 Regents Of The University Of Minnesota Process for the continuous culture of cells
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
ATE420114T1 (de) 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
WO2002088307A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
EP1404813A4 (en) 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
IL163525A0 (en) 2002-02-21 2005-12-18 Wyeth Corp A follistatin domain containing protein
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法

Also Published As

Publication number Publication date
JP2012095671A (ja) 2012-05-24
SV2006002212A (es) 2006-06-26
TW200615379A (en) 2006-05-16
IL181587A (en) 2011-03-31
JP2008511328A (ja) 2008-04-17
EP1781803A2 (en) 2007-05-09
CN101048512A (zh) 2007-10-03
ZA200702487B (en) 2011-10-26
EP1781803B1 (en) 2016-08-24
JP2015133980A (ja) 2015-07-27
EP2348126A3 (en) 2011-10-12
RU2007108718A (ru) 2008-10-10
US7335491B2 (en) 2008-02-26
ECSP077351A (es) 2008-03-26
TWI374935B (en) 2012-10-21
NZ591233A (en) 2012-09-28
BRPI0514680A (pt) 2008-06-17
PE20060715A1 (es) 2006-08-15
ES2599103T3 (es) 2017-01-31
AR050471A1 (es) 2006-10-25
CA2578137C (en) 2010-11-09
WO2006026408A2 (en) 2006-03-09
MY146097A (en) 2012-06-29
CA2578137A1 (en) 2006-03-09
NO20071571L (no) 2007-05-23
KR20070073737A (ko) 2007-07-10
IL181587A0 (en) 2007-07-04
KR100998857B1 (ko) 2010-12-08
SG155250A1 (en) 2009-09-30
UA89644C2 (ru) 2010-02-25
US20060160180A1 (en) 2006-07-20
PE20100147A1 (es) 2010-03-02
HN2005000486A (es) 2010-03-29
CN101048512B (zh) 2013-04-17
CR8996A (es) 2007-10-10
AU2005280090A1 (en) 2006-03-09
EG25848A (en) 2012-09-10
WO2006026408A3 (en) 2006-05-04
EP2348126A2 (en) 2011-07-27
RU2418858C2 (ru) 2011-05-20

Similar Documents

Publication Publication Date Title
MX2007002382A (es) Producci??n de anticuerpos anti-amiloides beta.
TW200619388A (en) Production of TNFR-lg
MX2007002380A (es) Produccion de polipeptidos.
Pump et al. Colonization of rice roots with methanogenic archaea controls photosynthesis‐derived methane emission
MX2010009984A (es) Selección de organismos capaces de fermentar sustratos mixtos.
MX2008016047A (es) Plantas que tienen rasgos mejorados relacionados con el crecimiento y un metodo para obtener las mismas.
MX2009007246A (es) Plantas con rasgos relacionados con el rendimiento mejorado y un metodo para producirlas.
ATE512229T1 (de) Neuer vektor und expressionszelllinie zur massenproduktion von rekombinantem protein sowie verfahren zur produktion von rekombinantem protein damit
TW200621980A (en) Anti-glypican 3 antibody having modified sugar chain
UA92157C2 (ru) Способ продуцирования гормона роста
Muñoz-Velasco et al. Methanogenesis on early stages of life: ancient but not primordial
ATE454458T1 (de) Pflanzen mit verbesserten wachstumseigenschaften und verfahren zu deren herstellung
WO2005089735A3 (en) Compositions and methods for treating lung cancer
TW200638944A (en) Recombinant enterovirus 71 neutralizing antibodies and use thereof
WO2008126783A1 (ja) ジペプチドの製造法
MX2010004699A (es) Plantas que tienen rasgos incrementados relacionados con el rendimiento y un metodo para producirlas.
IN2012DN01315A (enExample)
NO20073094L (no) Fremgangsmate for fremstilling av pattedyrceller
DE602005026811D1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
MX2010005716A (es) Polinucleotidos y metodos para mejorar plantas.
WO2007071578A3 (de) Verfahren zur herstellung von 5 -norbornen-2-carbonsäure aus 5-norbornen-2-carbonitril unter verwendung einer arylacetonitrilase
Dyksma Identification and activity of bacteria consuming key intermediates of carbon and sulfur cycling in coastal sands
Du e of Arc ycles
TH115320A (th) การผลิต-ABeta
Baggs et al. Denitrification and interactions between nitrification and methane oxidation under elevated atmospheric CO2

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights